Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun;59(6):803-812.
doi: 10.1038/s41409-024-02248-9. Epub 2024 Mar 4.

Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT

Jakob R Passweg  1 , Helen Baldomero  2 , Fabio Ciceri  3 , Rafael de la Cámara  4 , Bertram Glass  5 , Raffaella Greco  3 , Mette D Hazenberg  6 , Krzysztof Kalwak  7 , Donal P McLornan  8 , Bénédicte Neven  9 , Zinaida Perić  10 , Antonio M Risitano  11 , Annalisa Ruggeri  3 , John A Snowden  12 , Anna Sureda  13
Affiliations
Multicenter Study

Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT

Jakob R Passweg et al. Bone Marrow Transplant. 2024 Jun.

Abstract

In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were CAR-T. An additional 2854 patients received DLI. Changes compared to the previous year were an increase in CAR-T treatments (+27%) and decrease in allogeneic (-4.0%) and autologous HCT (-1.7%). Main indications for allogeneic HCT were myeloid malignancies (10,433; 58.4%), lymphoid malignancies (4,674; 26.2%) and non-malignant disorders (2572; 14.4%). Main indications for autologous HCT were lymphomas (7897; 32.9%), PCD (13,694; 57.1%) and solid tumors (1593; 6.6%). In allogeneic HCT, use of sibling donors decreased by -7.7%, haploidentical donors by -6.3% and unrelated donors by -0.9%. Overall cord blood HCT decreased by -16.0%. Use of allogeneic, and to a lesser degree autologous HCT, decreased for lymphoid malignancies likely reflecting availability of new treatment modalities, including small molecules, bispecific antibodies, and CAR-T cells. Pediatric HCT activity remains stable (+0.3%) with differences between allogeneic and autologous HCT. Use of CAR-T continues to increase and reached a cumulative total of 9039 patients treated with wide differences across European countries. After many years of continuous growth, increase in application of HCT seems to have slowed down.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Relative proportion of disease indications for HCT in 2022.
Green shades: myeloid malignancies, blue: lymphoid malignancies, brown: solid tumors and red: non malignant disorders. a Allogeneic 1st HCT. b Autologous 1st HCT.
Fig. 2
Fig. 2. Absolute numbers of patients treated in the years 1990 to 2022.
a Absolute numbers of patients receiving a first allogeneic or autologous HCT from 1990 to 2022. b Change in choice of donor from 1990 to 2022 (1st HCT).
Fig. 3
Fig. 3. Absolute numbers of HCT for Myeloma and NHL from 1990 to 2022.
a allogeneic 1st HCT. b autologous 1st HCT.
Fig. 4
Fig. 4
Absolute number of patients receiving CAR-T cellular therapy by indication from 2019 to 2022.
See this image and copyright information in PMC

References

    1. Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT) Bone Marrow Transpl. 1991;8:197–201. - PubMed
    1. Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34–44. doi: 10.1016/j.blre.2018.11.001. - DOI - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472. doi: 10.1056/NEJMp078166. - DOI - PubMed
    1. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39. doi: 10.1038/s41409-022-01691-w. - DOI - PMC - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed

Publication types